Virios Therapeutics (NASDAQ:VIRI) Given New $5.00 Price Target at HC Wainwright

Virios Therapeutics (NASDAQ:VIRI) had its price objective increased by HC Wainwright from $0.20 to $5.00 in a research report report published on Wednesday, Benzinga reports. The brokerage currently has a neutral rating on the stock.

Separately, Maxim Group began coverage on Virios Therapeutics in a report on Thursday, June 20th. They issued a buy rating and a $1.00 target price on the stock.

Virios Therapeutics Trading Down 27.0 %

Shares of NASDAQ VIRI opened at $2.83 on Wednesday. The firm has a market capitalization of $78.56 million, a P/E ratio of -10.48 and a beta of 1.58. The firm’s 50-day moving average price is $0.24 and its 200-day moving average price is $0.29. Virios Therapeutics has a 1-year low of $0.13 and a 1-year high of $1.04.

Virios Therapeutics (NASDAQ:VIRI) last issued its earnings results on Thursday, August 8th. The company reported ($0.05) EPS for the quarter, beating analysts’ consensus estimates of ($0.07) by $0.02. During the same period in the prior year, the business earned ($0.08) earnings per share. Equities research analysts forecast that Virios Therapeutics will post -0.22 EPS for the current year.

Virios Therapeutics Company Profile

Virios Therapeutics, Inc, a development-stage biotechnology company, focuses on developing novel antiviral therapies to treat diseases associated with a viral triggered abnormal immune response. The company's lead development candidate is the IMC-1, a fixed dose combination of famciclovir and celecoxib to treat fibromyalgia.